Khan Rishad, Habbal Mohamad, Scaffidi Michael A, Bukhari Abbas A, Rumman Amir, Al Ghamdi Sarah, Betschel Stephen D, Grover Samir C
Division of Gastroenterology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Division of Allergy and Clinical Immunology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
J Can Assoc Gastroenterol. 2020 Aug;3(4):162-168. doi: 10.1093/jcag/gwz004. Epub 2019 Feb 25.
Gastrointestinal (GI) symptoms are common among patients with common variable immunodeficiency disorder (CVID) yet remain poorly understood.
The aim of this study was to characterize the demographic, clinical, endoscopic and histologic features of patients with CVID and GI symptoms.
We conducted a retrospective observational study of all patients with CVID at a large Canadian tertiary care centre between January 2000 and May 2018.
We included 95 patients with CVID. The mean age of patients at the time of CVID diagnosis was 38.2(±16.0). Fifty-three (56%) patients were female. Sixty-four (67%) patients had GI symptoms, with a mean age of onset for GI symptoms of 43.4(±15.1) years. The most common symptoms were bowel movement changes ( = 55 [58%]) and abdominal pain ( = 44 [46%]). Patients with GI symptoms were more likely to have anemia ( = 23 [36%] versus = 3 [10%], = 0.0129), iron deficiency ( = 16 [25%] versus = 2 [7%], = 0.0481), and have received GI antibiotics ( = 37 [58%] versus = 0, < 0.0001) and proton pump inhibitors for reflux ( = 24 [38%] versus = 3 [10%], = 0.0067). The most common GI infections were ( = 14 [15%]) and ( = 4 [4%]). Forty-three (45%) patients with GI symptoms underwent colonoscopy, esophagogastroduodenoscopy or both. The most common findings were inflammation, nodular lymphoid hyperplasia, reduced plasma cells and increased intraepithelial lymphocytes.
This is the largest study on CVID patients in a North American setting. The majority of patients experienced GI symptoms. Future studies should study response to treatment for GI disease among patients with CVID.
胃肠道(GI)症状在普通可变免疫缺陷病(CVID)患者中很常见,但仍了解甚少。
本研究旨在描述CVID合并GI症状患者的人口统计学、临床、内镜及组织学特征。
我们对2000年1月至2018年5月期间加拿大一家大型三级医疗中心的所有CVID患者进行了一项回顾性观察研究。
我们纳入了95例CVID患者。CVID诊断时患者的平均年龄为38.2(±16.0)岁。53例(56%)患者为女性。64例(67%)患者有GI症状,GI症状的平均发病年龄为43.4(±15.1)岁。最常见的症状是排便习惯改变(n = 55 [58%])和腹痛(n = 44 [46%])。有GI症状的患者更易出现贫血(n = 23 [36%] 对比 n = 3 [10%],P = 0.0129)、缺铁(n = 16 [25%] 对比 n = 2 [7%],P = 0.0481),且更常接受治疗GI的抗生素(n = 37 [58%] 对比 n = 0,P < 0.0001)及用于反流的质子泵抑制剂(n = 24 [38%] 对比 n = 3 [10%],P = 0. .0067)。最常见的GI感染是弯曲杆菌(n = 14 [15%])和艰难梭菌(n = 4 [4%])。43例(45%)有GI症状的患者接受了结肠镜检查、食管胃十二指肠镜检查或两者均接受了检查。最常见的发现是炎症、结节状淋巴组织增生、浆细胞减少和上皮内淋巴细胞增多。
这是北美地区关于CVID患者的最大规模研究。大多数患者有GI症状。未来研究应探讨CVID患者对GI疾病治疗的反应。